Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Oriola

0.88 EUR+0.34 %15.9. klo 17.16
7,758 following

ORIOLA

NASDAQ Helsinki

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Short Selling
Investor views
Compare
+0.34 %
-2.44 %
-3.93 %
-12.70 %
-23.48 %
-24.79 %
-6.28 %
-52.94 %
-52.16 %

Oriola is a pharmaceutical group with a particular focus on the distribution of pharmaceuticals to other players in the industry. The company offers services to pharmacies and other pharmaceutical companies, which includes, for example, negotiations with suppliers and distribution of products. The largest operations are in the Nordic and Baltic regions. The headquarters are located in Espoo.

Read more
Market cap
163.09M EUR
Turnover
78.29K EUR
P/E (adj.) (26e)
EV/EBIT (adj.) (26e)
P/B (26e)
EV/S (26e)
Dividend yield-% (26e)
Coverage
Recommendation
Accumulate
Target price
Updated
20.07.2026
Disclaimer
Revenue and EBIT-%
EPS and dividend
Financial calendar
Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
3rd party
ShowingAll content types

Forum discussions
@Karo_Hamalainen’s interview featured Oriola’s CFO Mats Danielsson Oriola should have all the prerequisites to deliver good results. In its traditional core business, i.e., pharmaceutical distribution, it shares the Finnish market with Tamro. As the demand for medicines and the need...
9/9/2026, 6:05 AM
by Sijoittaja-alokas
7
The Chairman of the Board of Directors of Kronans Apotek, the Swedish pharmacy company half-owned by Oriola, has changed. According to the Swedish Trade Register, the new Chairman is Lars Gunnar Magnus Håkansson. He is an experienced Swedish business leader and professional board...
9/8/2026, 4:37 PM
by Aktivisti26
7
Here is the company report on Oriola from Rauli following the Q2 results Oriola’s Q2 results were slightly below our forecasts. We project that the company will barely reach the earnings improvement it guided for the full year. We estimate that Oriola has the potential for a moderately...
7/20/2026, 4:58 AM
by Sijoittaja-alokas
5
Regarding revenue, it is easier to expect a positive continuation from Kronans, but it could be affected by potential rationalization of the store network. I wouldn’t dare promise a positive trend for earnings development yet, as Kronans’ quarters have been quite volatile. The CEO...
7/17/2026, 10:01 AM
by Rauli_Juva
5
Here are Rauli’s quick comments on Oriola’s Q2 result Oriola’s Q2 report was operationally slightly softer than we expected, as the company’s adjusted EBITDA remained at the level of the comparison period and was slightly weaker than our forecasts. In particular, we expected an improvement...
7/17/2026, 6:51 AM
by Sijoittaja-alokas
5
Oriola has a solid track record of how to completely mess up with new ERP systems. The combination of Oriola and the renewal of an ERP system sends shivers down the spine of anyone who has ever invested in it. I was there once, paid my tuition fees – and will not return as an owner...
9/9/2026, 10:51 AM
by veikkan
4
[quote="Sijoittaja-alokas, post:1141, topic:1513"]\nand the new ERP system (toiminnanohjausjärjestelmä) is supposed to significantly improve Oriola’s efficiency, which should enable it to provide services more cost-effectively.\n[/quote]\n\nI was already wondering here if dementia...
9/9/2026, 9:19 AM
by Sndra
4
Read more on our forum
Rauli Juva
Rauli Juva

Analyst

Latest research

Latest analysis report

Released: 23.06.2026

Latest extensive report

Released: 23.06.2026

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
29.10.
2026

Interim report Q3'26

Oriola Q2'26: Headwinds from higher freight costs6:42
Video17.07.2026 klo 12.42 by
Rauli Juva

Oriola Q2'26: Headwinds from higher freight costs

Higher freight costs and increased operating expenses weighed on Oriola's earnings in Q2. Meanwhile, associate company Kronans improved its result compared with the corresponding period last year.

Oriola
Oriola, Webcast, Q2'26
Webcast17.07.2026 klo 10.00

Oriola, Webcast, Q2'26

Oriola
Regulatory press release17.07.2026 klo 08.30

Oriola Oyj: Oriola Corporation's Half-Year Report 1 January-30 June 2026

Oriola

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Press release03.07.2026 klo 09.00

Oriola Oyj: Oriola Corporation to publish its Half-Year Report for January-June 2026 on 17 July 2026

Oriola
Oriola Extensive Report: Patience prescribed
Extensive research23.06.2026 klo 12.15 by
Rauli Juva

Oriola Extensive Report: Patience prescribed

Oriola's stock looks cheap, but there are clear risks associated with both the balance sheet and operational activities.

Oriola
Regulatory press release12.06.2026 klo 17.00

Oriola Oyj: Oriola's share buyback programme has been completed

Oriola
Regulatory press release10.06.2026 klo 19.00

Oriola Oyj: Acquisition of own shares during week 24, 2026

Oriola
Regulatory press release10.06.2026 klo 15.30

Oriola Oyj: Composition of Oriola Corporation's Shareholders' Nomination Board

Oriola
Regulatory press release05.06.2026 klo 19.00

Oriola Oyj: Acquisition of own shares during week 23, 2026

Oriola
Regulatory press release05.06.2026 klo 13.00

CORRECTION: Oriola Corporation's Annual Report 2025 published

Oriola
Regulatory press release29.05.2026 klo 19.00

Oriola Oyj: Acquisition of own shares during week 22, 2026

Oriola
Regulatory press release22.05.2026 klo 19.00

Oriola Oyj: Acquisition of own shares during week 21, 2026

Oriola
Regulatory press release15.05.2026 klo 19.00

Oriola Oyj: Acquisition of own shares during week 20, 2026

Oriola
Third party research13.05.2026 klo 09.43

Oriola: Solid mid-term potential - Evli

With the financial targets announced earlier along with major investments known, Oriola’s CMD was limited in terms of significant new news, which we see as a positive given earlier concerns. More clarity was however provided on the roadmap to achieving...

Oriola
Press release11.05.2026 klo 13.00

Oriola Oyj: Oriola focuses on profitable growth and value creation at Capital Markets Day

Oriola
Regulatory press release08.05.2026 klo 19.00

Oriola Oyj: Acquisition of own shares during week 19, 2026

Oriola
Regulatory press release30.04.2026 klo 12.15

Oriola Oyj: Oriola Corporation - Managers' transactions - Pajamo

Oriola
Regulatory press release30.04.2026 klo 12.15

Oriola Oyj: Oriola Corporation - Managers' transactions - Axdorff

Oriola
Regulatory press release30.04.2026 klo 12.15

Oriola Oyj: Oriola Corporation - Managers' transactions - Westerlund

Oriola
Regulatory press release30.04.2026 klo 12.15

Oriola Oyj: Oriola Corporation - Managers' transactions - Carlsson Meyer

Oriola